Objective Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus confers a risk of significant coagulopathy, with the resulting development of venous …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Background Evidence supports an excess of deaths during the COVID-19 pandemic. We
report the incidence and mortality of thrombo-embolic events (TE) during the COVID-19 …

Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months,
causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation …

Background Infection by the 2019 novel coronavirus (COVID-19) has been reportedly
associated with a high risk of thrombotic complications. So far information is scarce and …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Data regarding the occurrence of venous thromboembolic events (VTE), including acute
pulmonary embolism (PE) and deep vein thrombosis (DVT) in recovered COVID-19 patients …

Abstract The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family …

The novel Corona virus infection (Covid-19) first identified in China in December 2019 has
rapidly progressed in pandemic leading to significant mortality and unprecedented …

The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening
multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with …